Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to …

Read more about 'Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors'...

Posted in Research; Posted 10 months ago 2 Minute(s) to read

Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing a…

Read more about 'Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy'...

Posted in Research; Posted 10 months ago 2 Minute(s) to read